Intensity Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Armistice Capital and Steven Boyd report a 2.56% beneficial ownership stake in Intensity Therapeutics, Inc. common stock.
NASDAQ
Sapient Capital LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 3.9% of Intensity Therapeutics, Inc.'s common stock as of June 30, 2025.
NASDAQ
Armistice Capital, LLC and Steven Boyd have disclosed a 5.75% beneficial ownership stake in Intensity Therapeutics, Inc., holding 872,547 shares of common stock.
NASDAQ
SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 8.13% Passive Stake in Intensity Therapeutics
Investment firm Armistice Capital, LLC and its managing member Steven Boyd have disclosed a passive beneficial ownership of 8.13% in Intensity Therapeutics, Inc. as of December 31, 2024.